FDA Guides Drugmakers on Bullseye Rash Lyme Fixes
Published Date: 6/26/2025
Notice
Summary
The FDA just released final advice to help drug makers create treatments for early Lyme disease, especially when it shows up as a bullseye rash called erythema migrans. This update affects companies working on Lyme disease drugs and aims to speed up safe, effective treatments hitting the market. No big cost changes yet, but faster drug development means better care for patients sooner!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA final guidance for Lyme drugs
The FDA released a final guidance titled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment" to help drug sponsors with the clinical development of treatments for early Lyme disease shown by an erythema migrans (EM) rash. This final guidance formalizes the draft guidance that was issued on February 1, 2023.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-11808, Elimination of Green and Energy Efficient Mortgage Insurance Premium Rate Category Applicable to Section 232 Mortgages
Starting now, healthcare facilities with FHA-insured loans won’t get special lower mortgage insurance rates for being green or energy-efficient. Instead, all these loans will follow the regular rate set before. This change affects anyone with Section 232 healthcare mortgages and means no extra savings for green upgrades.
Next: 2025-11810, South Atlantic Fishery Management Council (Council); Public Meetings
The South Atlantic Fishery Management Council is hosting a meeting from July 15-17, 2025, to talk about protecting ocean habitats and ecosystems. Fishermen, environmental groups, and coastal communities will get updates and can share their ideas. This meeting helps shape smart rules to keep fish and habitats healthy, with no immediate costs but big benefits for the future.